The role of imaging in screening special feaTure: review arTicle whole Body mri and oncology: recent major advances

MRI is a very attractive approach for tumour detection and oncological staging with its absence of ionizing radiation, high soft tissue contrast and spatial resolution. Less than 10 years ago the use of Whole Body MRI (WB-MRI) protocols was uncommon due to many limitations, such as the forbidding acquisition times and limited availability. This decade has marked substantial progress in WB-MRI protocols. This very promising technique is rapidly arising from the research world and is becoming a commonly used examination for tumour detection due to recent technological developments and validation of WB-MRI by multiple studies and consensus papers. As a result, WB-MRI is progres-sively proposed by radiologists as an efficient examination for an expanding range of indications. As the spectrum of its uses becomes wider, radiologists will soon be confronted with the challenges of this technique and be urged to be trained in order to accurately read and report these examinations. The aim of this review is to summarize the validated indications of WB-MRI and present an overview of its most recent advances. This paper will briefly discuss how this examination is performed and which are the recommended sequences along with the future perspectives in the field.

[1]  Jef Vandemeulebroucke,et al.  Registration strategies for multi‐modal whole‐body MRI mosaicing , 2018, Magnetic resonance in medicine.

[2]  Thomas Wiegel,et al.  Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. , 2018, European urology.

[3]  Y. Ohno,et al.  Diagnostic performance of different imaging modalities in the assessment of distant metastasis and local recurrence of tumor in patients with non‐small cell lung cancer , 2017, Journal of magnetic resonance imaging : JMRI.

[4]  David M. Thomas,et al.  Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis , 2017, JAMA oncology.

[5]  Simone Schrading,et al.  Abbreviated Biparametric Prostate MR Imaging in Men with Elevated Prostate-specific Antigen. , 2017, Radiology.

[6]  Caleb K. Stein,et al.  Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. , 2017, Blood.

[7]  Vicky Goh,et al.  Guidelines for the use of imaging in the management of patients with myeloma , 2017, British journal of haematology.

[8]  S. Punwani,et al.  Diagnostic utility of whole body Dixon MRI in multiple myeloma: A multi-reader study , 2017, PloS one.

[9]  Evis Sala,et al.  Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1‐Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy , 2017, The Journal of urology.

[10]  S. Rawal,et al.  A Comparative Study of 68Gallium-Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography and Magnetic Resonance Imaging for Lymph Node Staging in High Risk Prostate Cancer Patients: An Initial Experience , 2017, World journal of nuclear medicine.

[11]  Stuart A. Taylor,et al.  Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction , 2017, European Radiology.

[12]  A. Kural,et al.  The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  A. Padhani,et al.  The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer. , 2017, European journal of cancer.

[14]  J. Kuijer,et al.  Diffusion-weighted (DW) MRI in lung cancers: ADC test-retest repeatability , 2017, European Radiology.

[15]  M. Galia,et al.  Whole‐body MRI, FDG‐PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma , 2017, Journal of magnetic resonance imaging : JMRI.

[16]  D. Collins,et al.  Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. , 2017, Radiology.

[17]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[18]  E. Rummeny,et al.  11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer , 2017, Oncotarget.

[19]  E. Sala,et al.  METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer , 2017, European urology.

[20]  J. Sörensen,et al.  Whole-body MRI including diffusion-weighted MRI compared with 5-HTP PET/CT in the detection of neuroendocrine tumors , 2016, Upsala journal of medical sciences.

[21]  G. Karanikas,et al.  Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients , 2016, Clinical nuclear medicine.

[22]  M. Sokolska,et al.  Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response , 2016, British journal of haematology.

[23]  Henry Knipe,et al.  Oligometastases , 2016, Radiopaedia.org.

[24]  A. Bharatha,et al.  Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes. , 2016, Journal of the American Medical Association (JAMA).

[25]  P. Choyke,et al.  Prostate cancer: Birth of a standard: MET-RADS-P for metastatic prostate cancer , 2016, Nature Reviews Urology.

[26]  N. Michoux,et al.  Whole body MRI (WB‐MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease , 2016, The Prostate.

[27]  R. Kianmanesh,et al.  Impact of Liver and Whole-Body Diffusion-Weighted MRI for Neuroendocrine Tumors on Patient Management: A Pilot Study , 2016, Neuroendocrinology.

[28]  D. Collins,et al.  Inter- and Intra-Observer Repeatability of Quantitative Whole-Body, Diffusion-Weighted Imaging (WBDWI) in Metastatic Bone Disease , 2016, PloS one.

[29]  F. Lecouvet Whole-Body MR Imaging: Musculoskeletal Applications. , 2016, Radiology.

[30]  D. Moses,et al.  Magnetic resonance imaging in lung: a review of its potential for radiotherapy. , 2016, The British journal of radiology.

[31]  R. Braun,et al.  The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. , 2016, Swiss medical weekly.

[32]  Boudewijn P. F. Lelieveldt,et al.  Inter‐station intensity standardization for whole‐body MR data , 2016, Magnetic resonance in medicine.

[33]  P. Choyke,et al.  Combined Biparametric Prostate Magnetic Resonance Imaging and Prostate-specific Antigen in the Detection of Prostate Cancer: A Validation Study in a Biopsy-naive Patient Population. , 2016, Urology.

[34]  D. Collins,et al.  Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. , 2016, Radiology.

[35]  S. Fanti,et al.  Reply to the letter to the editor 'management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015' by Gillessen et al. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  K. Nichols,et al.  Diagnostic Performance of Whole-Body MRI as a Tool for Cancer Screening in Children With Genetic Cancer-Predisposing Conditions. , 2015, AJR. American journal of roentgenology.

[37]  D. Tárnoki,et al.  MR Diagnosis of Bone Metastases at 1.5 T and 3 T: Can STIR Imaging Be Omitted? , 2015, Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.

[38]  H. Ahlström,et al.  Whole body MRI, including diffusion-weighted imaging in follow-up of patients with testicular cancer , 2015, Acta oncologica.

[39]  M. Roach,et al.  Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. , 2015, European urology.

[40]  N. Michoux,et al.  wbMRI to detect bone metastases: critical review on diagnostic accuracy and comparison to other imaging modalities , 2015, Clinical and Translational Imaging.

[41]  N. Michoux,et al.  Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease. , 2015, Radiology.

[42]  Y. Akiyama,et al.  Iterative Decomposition of Water and Fat with Echo Asymmetry and Least-Squares Estimation (IDEAL) Magnetic Resonance Imaging as a Biomarker for Symptomatic Multiple Myeloma , 2015, PloS one.

[43]  Jian Hou,et al.  Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  T. Holland-Letz,et al.  The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[45]  Yan Liu,et al.  Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. , 2014, European journal of cancer.

[46]  G. Corradi,et al.  68Ga-DOTATATE PET/CT, 99mTc-HYNIC-Octreotide SPECT/CT, and Whole-Body MR Imaging in Detection of Neuroendocrine Tumors: A Prospective Trial , 2014, The Journal of Nuclear Medicine.

[47]  E. Lis,et al.  Whole‐body magnetic resonance imaging (WB‐MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: A pilot study , 2014, Pediatric blood & cancer.

[48]  M. Kersten,et al.  Potential prognostic implications of whole‐body bone marrow MRI in diffuse large B‐cell lymphoma patients with a negative blind bone marrow biopsy , 2014, Journal of magnetic resonance imaging : JMRI.

[49]  A. Shaaban,et al.  Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families , 2014, Familial Cancer.

[50]  Z. Jia,et al.  Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis , 2014, Skeletal Radiology.

[51]  Laurence Collette,et al.  One‐step TNM staging of high‐risk prostate cancer using magnetic resonance imaging (MRI): Toward an upfront simplified “all‐in‐one” imaging approach? , 2014, The Prostate.

[52]  D. Collins,et al.  Assessment of Treatment Response by Total Tumor Volume and Global Apparent Diffusion Coefficient Using Diffusion-Weighted MRI in Patients with Metastatic Bone Disease: A Feasibility Study , 2014, PloS one.

[53]  T. Holland-Letz,et al.  Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[54]  M. Weichenthal,et al.  Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma” , 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[55]  P. Summers,et al.  Whole-body diffusion-weighted imaging: is it all we need for detecting metastases in melanoma patients? , 2013, European Radiology.

[56]  M. Roethke,et al.  PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[57]  B. Tombal,et al.  Novel imaging techniques reshape the landscape in high-risk prostate cancers , 2013, Current opinion in urology.

[58]  Jingfei Ma,et al.  Conspicuity of bone metastases on fast Dixon-based multisequence whole-body MRI: clinical utility per sequence. , 2013, Magnetic resonance imaging.

[59]  Steve Halligan,et al.  Diffusion-weighted MRI of lymphoma: prognostic utility and implications for PET/MRI? , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[60]  G. Morgan,et al.  Assessing response of myeloma bone disease with diffusion-weighted MRI. , 2012, The British journal of radiology.

[61]  J. Sörensen,et al.  Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. , 2012, AJR. American journal of roentgenology.

[62]  D. Collins,et al.  Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls. , 2012, AJR. American journal of roentgenology.

[63]  Ronald M. Summers,et al.  Machine learning and radiology , 2012, Medical Image Anal..

[64]  M. Puderbach,et al.  MRI of the lung (1/3): methods , 2012, Insights into Imaging.

[65]  T. Derlin,et al.  Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation , 2012, European Radiology.

[66]  M. Reiser,et al.  FDG-PET-CT and whole-body MRI for triage in patients planned for radioembolisation therapy. , 2012, European journal of radiology.

[67]  M. Puderbach,et al.  MRI of the lung (2/3). Why … when … how? , 2012, Insights into Imaging.

[68]  Jingfei Ma,et al.  Fast dixon whole‐body MRI for detecting distant cancer metastasis: a preliminary clinical study , 2012, Journal of magnetic resonance imaging : JMRI.

[69]  M. Puderbach,et al.  MRI of the lung (3/3)—current applications and future perspectives , 2012, Insights into Imaging.

[70]  B. Tombal,et al.  Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over? , 2011, Advances in urology.

[71]  C. Meyer,et al.  Diffusion coefficient measurement using a temperature‐controlled fluid for quality control in multicenter studies , 2011, Journal of magnetic resonance imaging : JMRI.

[72]  D. Collins,et al.  Assessing response in bone metastases in prostate cancer with diffusion weighted MRI , 2011, European Radiology.

[73]  M. Forsting,et al.  "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases? , 2011, European journal of radiology.

[74]  M. Fenchel,et al.  Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results. , 2011, AJR. American journal of roentgenology.

[75]  J. Beyene,et al.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. , 2011, The Lancet. Oncology.

[76]  D. Collins,et al.  Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility , 2011, European Radiology.

[77]  Dominik Weishaupt,et al.  Diagnostic accuracy of whole-body MRI/DWI image fusion for detection of malignant tumours: a comparison with PET/CT , 2011, European Radiology.

[78]  P. Babyn,et al.  Imaging of cancer predisposition syndromes in children. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[79]  C. Barceló-Vidal,et al.  Comparative study of whole-body MRI and bone scintigraphy for the detection of bone metastases. , 2010, Clinical radiology.

[80]  Peter Boesiger,et al.  Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps--initial observations. , 2010, Radiology.

[81]  J. Hardes,et al.  Advantages in vascular tumors. , 2010, Deutsches Ärzteblatt International.

[82]  J. Felblinger,et al.  omparative study of two whole-body imaging techniques in the case of elanoma metastases : Advantages of multi-contrast MRI examination ncluding a diffusion-weighted sequence in comparison with PET-CT , 2010 .

[83]  Håkan Ahlström,et al.  Three‐point dixon method enables whole‐body water and fat imaging of obese subjects , 2010, Magnetic resonance in medicine.

[84]  R. Kluge,et al.  Whole-body MRI for primary evaluation of malignant disease in children. , 2010, European journal of radiology.

[85]  C. Binkert,et al.  Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma , 2010, Skeletal Radiology.

[86]  Marion de Jong,et al.  Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. , 2010, Endocrine-related cancer.

[87]  H. Amthauer,et al.  Impact of Multiphase 68Ga-DOTATOC-PET/CT on Therapy Management in Patients with Neuroendocrine Tumors , 2009, Neuroendocrinology.

[88]  H. Kauczor,et al.  Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. , 2009, Radiology.

[89]  Jingfei Ma,et al.  Fast dixon‐based multisequence and multiplanar MRI for whole‐body detection of cancer metastases , 2009, Journal of magnetic resonance imaging : JMRI.

[90]  S. Eustace,et al.  Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. , 2009, AJR. American journal of roentgenology.

[91]  D. Dearnaley,et al.  Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. , 2009, Clinical radiology.

[92]  S. Eustace,et al.  Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI) , 2009, Skeletal Radiology.

[93]  M. Reiser,et al.  Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer , 2009, European Radiology.

[94]  P. Choyke,et al.  Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. , 2009, Neoplasia.

[95]  D. Dearnaley,et al.  Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse , 2008, British Journal of Cancer.

[96]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  Y. Ohno,et al.  Whole‐body MR imaging vs. FDG‐PET: Comparison of accuracy of M‐stage diagnosis for lung cancer patients , 2007, Journal of magnetic resonance imaging : JMRI.

[98]  A. Runz,et al.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[99]  E. Winer,et al.  Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. , 2007, Breast.

[100]  C. Claussen,et al.  Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. , 2007, European journal of cancer.

[101]  D. Yang,et al.  Whole-body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy , 2006, Pediatric Radiology.

[102]  I. Magrath,et al.  Bone marrow involvement in young patients with non-Hodgkin's lymphoma: the importance of multiple bone marrow samples for accurate staging. , 2006, Medical and pediatric oncology.

[103]  T. Nazeer,et al.  Role of fluorine‐18 fluoro‐deoxyglucose positron emission tomography scan in the evaluation and follow‐up of patients with low‐grade lymphomas , 2006, Cancer.

[104]  T. Nägele,et al.  Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. , 2006, European journal of cancer.

[105]  S. Schoenberg,et al.  High-Resolution Whole-Body Magnetic Resonance Image Tumor Staging With the Use of Parallel Imaging Versus Dual-Modality Positron Emission Tomography–Computed Tomography: Experience on a 32-Channel System , 2005, Investigative radiology.

[106]  J. Connors,et al.  State-of-the-art therapeutics: Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  T. Takahara,et al.  Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. , 2004, Radiation medicine.

[108]  W. Heston,et al.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.

[109]  J. Debatin,et al.  Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. , 2003, JAMA.

[110]  A. Alavi,et al.  Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.

[111]  J. Biederer,et al.  Simulated pulmonary nodules implanted in a dedicated porcine chest phantom: sensitivity of MR imaging for detection. , 2003, Radiology.

[112]  Robin M Heidemann,et al.  Generalized autocalibrating partially parallel acquisitions (GRAPPA) , 2002, Magnetic resonance in medicine.

[113]  M. Slovak,et al.  Diagnostic utility of bilateral bone marrow examination , 2002, Cancer.

[114]  F. Algaba,et al.  EAU Guidelines on Testicular Cancer , 2001, European Urology.

[115]  R. Hustinx,et al.  Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[116]  R. Walker,et al.  Turbo STIR magnetic resonance imaging as a whole‐body screening tool for metastases in patients with breast carcinoma: Preliminary clinical experience , 2000, Journal of magnetic resonance imaging : JMRI.

[117]  E. Melhem,et al.  A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. , 1997, AJR. American journal of roentgenology.

[118]  J M Pauly,et al.  Lung parenchyma: projection reconstruction MR imaging. , 1991, Radiology.

[119]  P. Roemer,et al.  The NMR phased array , 1990, Magnetic resonance in medicine.

[120]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  D. Feinberg,et al.  Halving MR imaging time by conjugation: demonstration at 3.5 kG. , 1986, Radiology.

[122]  W. T. Dixon Simple proton spectroscopic imaging. , 1984, Radiology.

[123]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[124]  Michael R. Aro,et al.  Fat-suppression techniques for 3-T MR imaging of the musculoskeletal system. , 2014, Radiographics : a review publication of the Radiological Society of North America, Inc.

[125]  T Hielscher,et al.  Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma , 2014, Leukemia.

[126]  A. Horwich,et al.  [EAU guidelines on testicular cancer: 2011 update. European Association of Urology]. , 2012, Actas urologicas espanolas.

[127]  N. deSouza,et al.  Diffusion Weighted Magnetic Resonance Imaging of metastatic bone disease: A biomarker for treatment response monitoring. , 2010, Cancer biomarkers : section A of Disease markers.

[128]  S. Schoenberg,et al.  Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. , 2008, European journal of radiology.

[129]  R. Fanin,et al.  A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. , 2007, Haematologica.

[130]  M. Langer,et al.  [Whole-body MRI in comparison to skeletal scintigraphy for detection of skeletal metastases in patients with solid tumors]. , 2004, Der Radiologe.

[131]  E. Imhoff,et al.  Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer , 2004, European Radiology.

[132]  O. Tanaka,et al.  Clinical and prognostic significance of femoral marrow magnetic resonance imaging in patients with malignant lymphoma. , 1997, Blood.

[133]  H. Gralnick,et al.  Frequencies and patterns of bone marrow involvement in non‐hodgkin lymphomas: Observations on the value of bilateral biopsies , 1977, American journal of hematology.